Moberg Pharma Nails Antifungal Drug Agreement with Bayer, an Industrial Info Market Brief
Moberg Pharma Nails Antifungal Drug Agreement with Bayer, an Industrial Info Market Brief
Attachment: Bayer
Moberg Pharma has entered into an exclusive agreement with Bayer for the marketing, distribution and sales of its MOB-015 drug, which is used in the topical treatment of onychomycosis, a fungal infection of the nail. This gives Bayer exclusive European rights to MOB-015 upon completion of Phase II clinical development and registration.
Bayer has 15 operational sites in Europe. See map below.
Subscribe Now!(All Fields Required)
Related Articles
Articles related to this company
- México registra inversiones por 2 mil millones de dólares en el sector farm...
- Mexico Registers US$2 Billion in Pharmaceutical Investments
- New England Sees $27 Billion in Projects Under Construction
- Pharma, Manufacturing Lead Indiana to $21.6 Billion of Projects Under Const...
- India Aims to Reduce Dependence on China for Pharma Market